Xilio Therapeutics Inc —— 季度资产负债表 (NASDAQ:XLO) | MetaTrader

展开完整图表

新闻

Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market

Xilio Therapeutics实施1股并14股的反向拆股

Xilio Therapeutics implements 1-for-14 reverse stock split

西利奥治疗公司从权证行权中获得3580万美元

Xilio Therapeutics secures $35.8 million from warrant exercises

Xilio Therapeutics报告从B系列权证行权中获得3580万美元收益

Xilio Development Q3 每股收益逊于预期, 营收超出预期

Xilio Development earnings missed by $0.06, revenue topped estimates

Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates

Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC - Slideshow (NASDAQ:XLO) 2025-11-11

Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript